TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15010695

Group type: EXPERIMENTAL
Intervention: 21 mg/day nicotine transdermal patch
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo transdermal patch
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (15 and 30 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (200 and 400 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Number of subjects: 9
Study: 11273861

Group type: EXPERIMENTAL
Intervention: Refeeding intervention in malnourished subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study: 9550480

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (aCL) presence in patients with giant cell arteritis
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Temporal arteritis biopsy positive
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Temporal arteritis biopsy negative
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Thrombotic complications associated with aCL
Number of subjects: 284
Study: 8148435

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention for chronic fatigue syndrome (CFS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention for primary depression
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (control group) for chronic fatigue syndrome (CFS)
Number of subjects: 22
Study: 2459174

Group type: EXPERIMENTAL
Intervention: Compound 48/80 at 2.4 mg/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compound 48/80 at 0.6 mg/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compound 48/80 at concentrations less than 0.6 mg/ml
Number of subjects: 0
Study: 29382813

Group type: EXPERIMENTAL
Intervention: Succinylated gelatin (12 ml/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hypertonic sodium chloride hydroxyethyl starch 40 injection
Number of subjects: 70
Study: 27544892

Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) intravenous injection before carotid endarterectomy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intracoronary NIRF-OCT imaging in swine
Number of subjects: 8
Study: 25642916

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 23000323

Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System (CDSS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regional guideline in paper format (Control)
Number of subjects: 60
Study: 19748249

Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction diet (20-25% energy from carbohydrate) for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Combination treatment: Carbohydrate restriction diet for 6 weeks followed by American Heart Association diet (50-55% CHO) for an additional 6 weeks
Number of subjects: 39
Study: 18444711

Group type: EXPERIMENTAL
Intervention: ADHD/Rx
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ADHD/TN
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ADHD groups
Number of subjects: 94
Study: 16551147

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Community referral
Number of subjects: 267
Study: 14737930

Group type: EXPERIMENTAL
Intervention: Long poles
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal poles
Number of subjects: 7

Group type: COMPARATOR
Intervention: Short poles
Number of subjects: 7
Study: 10639539

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg once per day orally)
Number of subjects: 9297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study: 9181442

Group type: EXPERIMENTAL
Intervention: Bolus injection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Drip infusion
Number of subjects: 27
Study: 7694148

Group type: EXPERIMENTAL
Intervention: esc-BACOP (escalated doses of doxorubicin)
Number of subjects: 238

Group type: COMPARATOR
Intervention: s-BACOP (standard doses of doxorubicin)
Number of subjects: 238
Study: 3898228

Group type: EXPERIMENTAL
Intervention: desglycinamide arginine vasopressin (DGAVP)
Number of subjects: 0
Study: 31666783

Group type: EXPERIMENTAL
Intervention: Parasitological confirmed malaria
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Living in rural residence
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Having educated mother
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Age of child
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Sex of child
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Not sleeping under ITN
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: ITN availability
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: History of malaria infection among family members
Number of subjects: 484
Study: 28853340

Group type: EXPERIMENTAL
Intervention: Feeling consistently Good
Number of subjects: 387

Group type: COMPARATOR
Intervention: Moderate reactions
Number of subjects: 387

Group type: COMPARATOR
Intervention: Pronounced reactions
Number of subjects: 387

Group type: COMPARATOR
Intervention: Neutral reactions
Number of subjects: 387

Group type: COMPARATOR
Intervention: Pronounced pattern among Black subjects
Number of subjects: 387
Study: 27448264

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Brief Systemic Therapy (BST)
Number of subjects: 419
Study: 24616894

Group type: EXPERIMENTAL
Intervention: Exercise and educational-behavioral programme (EG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study: 21953578

Group type: EXPERIMENTAL
Intervention: Face-to-face sexual counseling (FF)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Internet-based sexual counseling (WEB1)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Internet-based sexual counseling (WEB2)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 115
Study: 20179144

Group type: EXPERIMENTAL
Intervention: TMD with VOO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TMD with WOO
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control with participants' habitual diet
Number of subjects: 90
Study: 17270578

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with feminine introductions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with masculine introductions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with gender-irrelevant introductions
Number of subjects: 151
Study: 12780836

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Neodymium: YAG laser therapy
Number of subjects: 180
Study: 10850578

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven) as a single intravenous bolus dose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 36
Study: 15321288

Group type: EXPERIMENTAL
Intervention: Meptazinol (10 mg PCA bolus)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Morphine (1 mg PCA bolus)
Number of subjects: 48
Study: 8238798

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg daily for 2 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice daily for 2 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: loratadine after crossover for nonresponders to terfenadine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: terfenadine after crossover for nonresponders to loratadine
Number of subjects: 76
Study: 3884566

Group type: EXPERIMENTAL
Intervention: latamoxef (moxalactam)
Number of subjects: 60

Group type: COMPARATOR
Intervention: cephradine plus tobramycin
Number of subjects: 60
Study: 31010031

Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (SCP) 15 g daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 28834186

Group type: EXPERIMENTAL
Intervention: Mifepristone alone (n = 27)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Osmotic dilators with mifepristone (n = 27)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Osmotic dilators with placebo (n = 21)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study: 25230069

Group type: EXPERIMENTAL
Intervention: Salbutamol (4mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23625328

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily
Number of subjects: 64
Study: 21799398

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study: 19548488

Group type: EXPERIMENTAL
Intervention: Chlorine dioxide waterline cleaner treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (untreated lines)
Number of subjects: 6
Study: 17806055

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg daily
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg daily
Number of subjects: 595

Group type: COMPARATOR
Intervention: Caspofungin (70 mg followed by 50 mg daily)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 595
Study: 15471825

Group type: EXPERIMENTAL
Intervention: Carvedilol, 50 mg/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carvedilol or Metoprolol
Number of subjects: 36
Study: 11058707

Group type: EXPERIMENTAL
Intervention: Omacor (4 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 28
Study: 8874910

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg. kg‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Atracurium (0.5 mg. kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg. kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg. kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium (2 x ED95 doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium (3 x ED95 doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cisatracurium (4 x ED95 doses)
Number of subjects: 80
Study: 1328143

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMW-heparins) administered subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical intravenous heparin therapy
Number of subjects: 0
Study: 4061268

Group type: EXPERIMENTAL
Intervention: Intravenous timolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30509746

Group type: EXPERIMENTAL
Intervention: Trifocal spherical hydrophilic IOL (FineVision POD F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifocal toric hydrophilic IOL (FineVision POD FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both IOLs
Number of subjects: 0
Study: 29316152

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carboxytherapy session
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carboxytherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 20
Study: 27760933

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using FP(CF) plus docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using FP(CF) plus radiation (FP(CF)-RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using FP(CF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using DCF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using FP(CF)-RT
Number of subjects: 0
Study: 25623102

Group type: EXPERIMENTAL
Intervention: PHILOS
Number of subjects: 284

Group type: COMPARATOR
Intervention: LPHP
Number of subjects: 284
Study: 24295145

Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study: 20585755

Group type: EXPERIMENTAL
Intervention: Electrical stimulation treatment (10 treatments vaginally and transanally over 5-7 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tolterodine 4 mg orally once daily
Number of subjects: 61
Study: 18180882

Group type: EXPERIMENTAL
Intervention: Milk-powder-based dietary supplement providing 50 mg Ca, 250 mg Ca, or 500 mg Ca, or 500 mg Ca plus multivitamins, iron, and zinc, given daily, 6 days/week for 13 months.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Milk-powder-based dietary supplement providing 50 mg Ca (lowest amount).
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pre-trial period (7 months) with no intervention.
Number of subjects: 158
Study: 16868704

Group type: EXPERIMENTAL
Intervention: Standard calcium and magnesium dialysis solution (SCa-MgD) (Ca: 1.62 mmol/l, Mg: 0.75 mmol/l)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low calcium and magnesium dialysis solution (LCa-MgD) (Ca: 1.25 mmol/l, Mg: 0.25 mmol/l)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 12786634

Group type: EXPERIMENTAL
Intervention: Pantoprazole, 20 mg daily for 6 months
Number of subjects: 164
Study: 10958047

Group type: EXPERIMENTAL
Intervention: Thermomagnetic bandages and belts worn for 8 hours a day for 14 consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (non-magnetic devices)
Number of subjects: 60
Study: 8805033

Group type: COMPARATOR
Intervention: Growth hormone treatment in short normal children
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chemotherapy in children with acute lymphoblastic leukaemia
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-dose dexamethasone in babies with bronchopulmonary dysplasia
Number of subjects: 50
Study: 1535301

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous methylprednisolone at 8 AM
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous methylprednisolone at 4 PM
Number of subjects: 6

Group type: COMPARATOR
Intervention: No drug administration
Number of subjects: 6
Study: 31144279

Group type: EXPERIMENTAL
Intervention: Transitional Care (TC) intervention
Number of subjects: 654

Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 654
Study: 27614145

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of midodrine and tolvaptan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 50
Study: 24963091

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied during water swallows
Number of subjects: 26

Group type: COMPARATOR
Intervention: Water swallows without NMES
Number of subjects: 26
Study: 23370049

Group type: EXPERIMENTAL
Intervention: Yo-Yo intermittent recovery test level 1 (Yo-Yo IR1) training, 6-week program, twice a week
Number of subjects: 25

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 25
Study: 22171201

Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, and Rescripting Therapy (ERRT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 47
Study: 21524761

Group type: EXPERIMENTAL
Intervention: QuantiFERON(®)-TB Gold In-Tube (QF)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Tuberculin skin test (PPD)
Number of subjects: 376
Study: 17587516

Group type: EXPERIMENTAL
Intervention: isopropanolic extract of Actaea racemosa (iCR, Remifemin) 40 mg crude drug/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: tibolone 2.5 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: isopropanolic extract of Actaea racemosa (iCR, Remifemin)
Number of subjects: 244

Group type: COMPARATOR
Intervention: tibolone
Number of subjects: 244
Study: 16282305

Group type: EXPERIMENTAL
Intervention: Safe water system (SWS) with hygiene education
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Safe water system (SWS) with hygiene education and cotrimoxazole prophylaxis
Number of subjects: 509
Study: 12015521

Group type: EXPERIMENTAL
Intervention: Oral estrogen/medroxyprogesterone acetate (HRT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oral estrogen (ERT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9857542

Group type: EXPERIMENTAL
Intervention: Face-bow and Quick Master articulator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional method (Gysi method)
Number of subjects: 60
Study: 7818158

Group type: EXPERIMENTAL
Intervention: Capillary microscopy
Number of subjects: 522

Group type: COMPARATOR
Intervention: Digital blood pressure measurements
Number of subjects: 522
Study: 2211564

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 40
Study: 341947

Group type: EXPERIMENTAL
Intervention: Single night-time dose of mianserin 60 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three times daily regimen of mianserin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels above 70 microgram/1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels in patients over 55
Number of subjects: 50
Study: 31774552

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 80
Study: 31042649

Group type: EXPERIMENTAL
Intervention: Bilateral interlaminar canal decompression
Number of subjects: 218

Group type: COMPARATOR
Intervention: Classic laminectomy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218
Study: 28580357

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 14
Study: 26237520

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (daily 50,000 IU vitamin D3)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Low-dose cholecalciferol (daily 800 IU vitamin D3)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (daily white and twice monthly yellow placebo)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Low-dose cholecalciferol
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 23602388

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 22
Study: 21716250

Group type: COMPARATOR
Intervention: Phenobarbital (group 1, 34 patients)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Topiramate (group 2, 31 patients)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lamotrigine (group 3, 31 patients)
Number of subjects: 96
Study: 19598025

Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 211
Study: 16436824

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy with SPECT prior to injection (Group A1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Facet joint injections at levels indicated by referring physician without bone scintigraphy (Group B)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Facet joint injections at levels decided as in group B (Group A2)
Number of subjects: 47
Study: 15327411

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 30 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11700777

Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 0
Study: 9315530

Group type: EXPERIMENTAL
Intervention: Tirofiban (10 microg/kg bolus over 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) infusion for 36 hours)
Number of subjects: 2139

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2139
Study: 8328844

Group type: EXPERIMENTAL
Intervention: Autotransfusion for 12 hours after surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard chest drainage and fluid replacement (Control)
Number of subjects: 35
Study: 3574819

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cefazolin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Three perioperative doses of cefazolin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Single dose of cefonicid
Number of subjects: 135
Study: 29698927

Group type: EXPERIMENTAL
Intervention: trastuzumab plus capecitabine (HX)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: lapatinib plus capecitabine (LX)
Number of subjects: 86
Study: 27279544

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once a day)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Everolimus (10 mg once a day)
Number of subjects: 658
Study: 23567376

Group type: EXPERIMENTAL
Intervention: Telehealth problem-solving therapy (tele-PST)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: In-person problem-solving therapy (PST)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Telephone support calls
Number of subjects: 121
Study: 23226893

Group type: EXPERIMENTAL
Intervention: Psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Physician treatment
Number of subjects: 2181